InformedGENOMICS™ gives your teams the guidance they need, all in one place and at their fingertips! Alleviate Pressure on Staff Decrease Unnecessary Spending Reduce Appeal Rates Without ready access to clinical genomics expertise, health plans’ medical reviewers and policy writers are at risk of using outdated resources to inform coverage policies and decisions, resulting in …
Genetic testing has quickly grown from being very rare, to prominently weaving into prenatal care, cancer care, and nearly all specialties of medicine including neurology, cardiology, and ophthalmology. To understand how health plans are integrating this rapidly changing test landscape into their genomic benefits management (GBM) approach, InformedDNA partnered with medical technology service provider, Veranex, …
Health Plans Speak: We Are Under-Resourced to Address Growth in Genomics Read More »
If they haven’t already, health plans will soon see a rapid rise in the number of members and providers asking whether genomic testing is covered and to what degree. Even though genomic testing may be a small part of a health plan’s benefit management program it can represent a meaningful portion of the risk. And a risk that will only increase if the health plan does not have a well-designed genomics benefit management (GBM) plan in place.
Because of the increasing interest in the development of therapeutics for genetic conditions and rare diseases, we wanted to sit down with our VP of Life Sciences Business Development Sean Sigmon to get his perspective on what some forward-thinking organizations are doing to augment their go-to-market plans. We want to help others understand some of the unique approaches that can be deployed when it comes to improving post-market access for genomic-based therapies. The following questions and answers highlight some concepts we believe biopharma marketers, commercial and market access teams should give strong consideration to.
Appropriate clinical guidance is the cornerstone of any health plan benefits management program when it comes to genomics in healthcare.
However, writing and maintaining appropriate genomic coverage policies in-house poses unique challenges for most health plans. Genomic coverage guidelines must address many factors in the face of rapidly changing genomic science and a rapidly expanding test landscape.
By Heather Dorsey, Evidence Review Manager, M.S., CGC and Kelly Athman, Senior Director of Medical Affairs, M.S., CGC What is a liquid biopsy anyway? Your mind may be swirling with this and other questions, especially when it comes to more media coverage on these types of tests, like the recent article in The New York …
What Patients, Providers, and Payors Should Know About Liquid Biopsies Read More »
By Rebecca Sutphen, MD, FACMGG, Co-Founder and Chief Medical Officer, InformedDNA, and Karmen Trzupek, MS, Board-Certified Genetic Counselor Diversity in all clinical research—including rare disease research—is currently under scrutiny, partly because of disparities experienced with COVID-19. Rightly so, as data show that 86% of genomics studies to date have involved people of European ancestry, which …
Strategies to Increase Diversity in Rare Genetic Disease Clinical Trials Read More »
InformedDNA provides expert genetics services to foundations and patient advocacy organizations. We’ve successfully addressed the challenge that many foundations face in supporting patients through the genetic testing and screening process necessary to identify appropriate candidates for clinical trials. We also help patient foundations to effectively leverage their outreach capabilities to engage pharmaceutical companies while continuing …
Executive Summary, by InformedDNA Precision medicine that harnesses advances in genomics holds enormous promise for impacting every aspect of a health plan’s business. When properly integrated, genomics enables more tailored care with the potential for tremendously improved outcomes–especially in specialties such as oncology and reproductive health. Genomics is a technically complex discipline with a growing …
Achieving Value through Comprehensive Genomic Benefits Management (GBM) Read More »
When patients hear from their healthcare providers that they may be good candidates for genetic testing, they typically have questions…or they may not even know what questions they should be asking in order to consent or not in an informed way. That is when genetic counseling should come into the picture. Pre-test genetic counseling, or …
The Value of Pre-Test Genetic Counseling for Health Plans, Providers, and Patients Read More »
Copyright ©2023 InformedDNA® All Rights Reserved